These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32194148)

  • 1. Prior event rate ratio adjustment produced estimates consistent with randomized trial: a diabetes case study.
    Rodgers LR; Dennis JM; Shields BM; Mounce L; Fisher I; Hattersley AT; Henley WE;
    J Clin Epidemiol; 2020 Jun; 122():78-86. PubMed ID: 32194148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.
    Dennis JM; Henley WE; Weedon MN; Lonergan M; Rodgers LR; Jones AG; Hamilton WT; Sattar N; Janmohamed S; Holman RR; Pearson ER; Shields BM; Hattersley AT;
    Diabetes Care; 2018 Sep; 41(9):1844-1853. PubMed ID: 30072404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term comparative safety analysis of the risks associated with adding or switching to a sulfonylurea as second-line Type 2 diabetes mellitus treatment in a US veteran population.
    Powell WR; Christiansen CL; Miller DR
    Diabet Med; 2019 Nov; 36(11):1384-1390. PubMed ID: 30343492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
    Foroutan N; Muratov S; Levine M
    Clin Invest Med; 2016 Apr; 39(2):E48-62. PubMed ID: 27040861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
    Tsilidis KK; Capothanassi D; Allen NE; Rizos EC; Lopez DS; van Veldhoven K; Sacerdote C; Ashby D; Vineis P; Tzoulaki I; Ioannidis JP
    Diabetes Care; 2014 Sep; 37(9):2522-32. PubMed ID: 24898303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
    Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
    Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: A population-based cohort study.
    Wang JL; Dong YH; Ko WC; Chang CH; Wu LC; Chuang LM; Chen PC
    Diabetes Obes Metab; 2018 Dec; 20(12):2811-2820. PubMed ID: 29974616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
    Yu O; Azoulay L; Yin H; Filion KB; Suissa S
    Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
    Bloomgarden ZT
    Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
    [No Abstract]   [Full Text] [Related]  

  • 16. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
    Bowker SL; Majumdar SR; Veugelers P; Johnson JA
    Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials.
    Rajagopalan R; Iyer S; Khan M
    Curr Med Res Opin; 2005 Jan; 21(1):163-72. PubMed ID: 15881488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior event rate ratio adjustment: numerical studies of a statistical method to address unrecognized confounding in observational studies.
    Yu M; Xie D; Wang X; Weiner MG; Tannen RL
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():60-8. PubMed ID: 22552981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.